Bogart Wealth LLC Has $95,000 Holdings in Danaher Corporation $DHR

Key Points

• Bogart Wealth LLC significantly reduced its **holdings in Danaher Corporation** by **98.4%**, now owning just **481 shares worth $95,000** after selling nearly 30,000 shares.
• Danaher announced a **quarterly dividend** of **$0.32 per share**, set to be paid on **October 31st**, which represents an annualized yield of **0.6%**.
• Several institutional investors, including **Vanguard Group** and **Price T Rowe Associates**, have been increasing their stakes in Danaher, highlighting strong interest in the stock as **79.05%** of it is currently owned by such investors.

Bogart Wealth LLC cut its holdings in Danaher Corporation (NYSE:DHR - Free Report) by 98.4% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 481 shares of the conglomerate's stock after selling 29,966 shares during the period. Bogart Wealth LLC's holdings in Danaher were worth $95,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Vanguard Group Inc. raised its holdings in shares of Danaher by 0.4% in the first quarter. Vanguard Group Inc. now owns 59,981,088 shares of the conglomerate's stock valued at $12,296,123,000 after purchasing an additional 230,966 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Danaher by 3.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate's stock valued at $4,016,404,000 after purchasing an additional 612,154 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Danaher by 2.3% in the first quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate's stock valued at $1,800,614,000 after purchasing an additional 194,466 shares during the last quarter. Invesco Ltd. raised its holdings in shares of Danaher by 44.5% in the first quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate's stock valued at $965,259,000 after purchasing an additional 1,450,703 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Danaher by 4.0% in the first quarter. Charles Schwab Investment Management Inc. now owns 4,230,087 shares of the conglomerate's stock valued at $867,168,000 after purchasing an additional 163,332 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Danaher

In other news, Director Teri List sold 2,778 shares of Danaher stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the sale, the director owned 20,751 shares of the company's stock, valued at approximately $4,379,706.06. This trade represents a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 11.20% of the company's stock.

Danaher Trading Down 0.5%

DHR stock opened at $208.06 on Tuesday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. The company has a fifty day moving average price of $201.76 and a two-hundred day moving average price of $197.42. Danaher Corporation has a one year low of $171.00 and a one year high of $274.21. The stock has a market cap of $148.98 billion, a price-to-earnings ratio of 44.27, a price-to-earnings-growth ratio of 2.98 and a beta of 0.77.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, topping analysts' consensus estimates of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The firm had revenue of $5.94 billion during the quarter, compared to analysts' expectations of $5.83 billion. During the same period in the previous year, the business posted $1.72 earnings per share. The company's revenue for the quarter was up 3.4% compared to the same quarter last year. Equities analysts anticipate that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Friday, September 26th. Danaher's payout ratio is 27.23%.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Royal Bank Of Canada set a $241.00 target price on shares of Danaher in a research note on Tuesday, September 2nd. UBS Group decreased their target price on shares of Danaher from $240.00 to $225.00 and set a "buy" rating for the company in a research note on Wednesday, July 23rd. Guggenheim reissued a "buy" rating and issued a $250.00 target price on shares of Danaher in a research note on Wednesday, July 23rd. Evercore ISI raised their target price on shares of Danaher from $226.00 to $245.00 and gave the company an "outperform" rating in a research note on Tuesday, October 7th. Finally, Rothschild Redb cut shares of Danaher from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, October 8th. Seventeen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, Danaher has an average rating of "Moderate Buy" and a consensus price target of $245.00.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.